6.77 USD
-0.09 (-1.31%)
6.77 USD
0 (0%)
MDXG gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. MDXG has an excellent financial health rating, but there are some minor concerns on its profitability. MDXG scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make MDXG suitable for value investing!
1. Profitability
1.1 Basic Checks
MDXG had positive earnings in the past year.
In the past year MDXG had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MDXG reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: MDXG reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of MDXG (12.80%) is better than 94.53% of its industry peers.
MDXG's Return On Equity of 17.09% is amongst the best of the industry. MDXG outperforms 95.09% of its industry peers.
MDXG's Return On Invested Capital of 15.15% is amongst the best of the industry. MDXG outperforms 95.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROIC | 15.15% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDXG has a Profit Margin of 10.38%. This is amongst the best in the industry. MDXG outperforms 91.32% of its industry peers.
With an excellent Operating Margin value of 13.73%, MDXG belongs to the best of the industry, outperforming 92.83% of the companies in the same industry.
MDXG's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 81.99%, MDXG belongs to the top of the industry, outperforming 85.66% of the companies in the same industry.
MDXG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MDXG is creating some value.
Compared to 1 year ago, MDXG has more shares outstanding
The number of shares outstanding for MDXG has been increased compared to 5 years ago.
MDXG has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 9.79 indicates that MDXG is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 9.79, MDXG belongs to the top of the industry, outperforming 81.51% of the companies in the same industry.
MDXG has a debt to FCF ratio of 0.27. This is a very positive value and a sign of high solvency as it would only need 0.27 years to pay back of all of its debts.
The Debt to FCF ratio of MDXG (0.27) is better than 95.47% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that MDXG is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.07, MDXG is not doing good in the industry: 60.75% of the companies in the same industry are doing better.
Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Altman-Z | 9.79 |
ROIC/WACC1.75
WACC8.68%
2.3 Liquidity
MDXG has a Current Ratio of 4.41. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
MDXG has a Current ratio of 4.41. This is comparable to the rest of the industry: MDXG outperforms 51.13% of its industry peers.
A Quick Ratio of 3.95 indicates that MDXG has no problem at all paying its short term obligations.
MDXG has a Quick ratio (3.95) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
MDXG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.71%.
Looking at the last year, MDXG shows a quite strong growth in Revenue. The Revenue has grown by 14.77% in the last year.
MDXG shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.11% yearly.
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
3.2 Future
The Earnings Per Share is expected to grow by 16.54% on average over the next years. This is quite good.
The Revenue is expected to grow by 14.49% on average over the next years. This is quite good.
EPS Next Y47.72%
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
EPS Next 5YN/A
Revenue Next Year18%
Revenue Next 2Y9.77%
Revenue Next 3Y10.75%
Revenue Next 5Y14.49%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 18.81, which indicates a rather expensive current valuation of MDXG.
Compared to the rest of the industry, the Price/Earnings ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 94.72% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.51. MDXG is valued slightly cheaper when compared to this.
MDXG is valuated quite expensively with a Price/Forward Earnings ratio of 27.09.
MDXG's Price/Forward Earnings ratio is rather cheap when compared to the industry. MDXG is cheaper than 92.64% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.13, MDXG is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.81 | ||
| Fwd PE | 27.09 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 95.47% of the companies listed in the same industry.
96.98% of the companies in the same industry are more expensive than MDXG, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.01 | ||
| EV/EBITDA | 12.8 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MDXG has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MDXG's earnings are expected to grow with 16.54% in the coming years.
PEG (NY)0.39
PEG (5Y)N/A
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
5. Dividend
5.1 Amount
MDXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
6.77
-0.09 (-1.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.78%
Inst Owner Change-0.7%
Ins Owners1.79%
Ins Owner Change-0.13%
Market Cap1.00B
Revenue(TTM)393.44M
Net Income(TTM)40.83M
Analysts81.82
Price Target12.44 (83.75%)
Short Float %3.16%
Short Ratio4.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.82%
Min EPS beat(2)81.55%
Max EPS beat(2)110.08%
EPS beat(4)3
Avg EPS beat(4)41.67%
Min EPS beat(4)-31.92%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)78.91%
EPS beat(12)11
Avg EPS beat(12)70.05%
EPS beat(16)12
Avg EPS beat(16)53.63%
Revenue beat(2)2
Avg Revenue beat(2)12.56%
Min Revenue beat(2)6.68%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)6.82%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)3.48%
Revenue beat(12)9
Avg Revenue beat(12)3.71%
Revenue beat(16)12
Avg Revenue beat(16)3.45%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.15%
EPS NY rev (1m)-1.18%
EPS NY rev (3m)29.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.37%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)5.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.81 | ||
| Fwd PE | 27.09 | ||
| P/S | 2.55 | ||
| P/FCF | 15.01 | ||
| P/OCF | 14.78 | ||
| P/B | 4.2 | ||
| P/tB | 4.81 | ||
| EV/EBITDA | 12.8 |
EPS(TTM)0.36
EY5.32%
EPS(NY)0.25
Fwd EY3.69%
FCF(TTM)0.45
FCFY6.66%
OCF(TTM)0.46
OCFY6.77%
SpS2.66
BVpS1.61
TBVpS1.41
PEG (NY)0.39
PEG (5Y)N/A
Graham Number3.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROCE | 20.67% | ||
| ROIC | 15.15% | ||
| ROICexc | 33.2% | ||
| ROICexgc | 44.66% | ||
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% | ||
| FCFM | 16.98% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score6
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 6.96% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 36.69 | ||
| Cash Conversion | 98.8% | ||
| Profit Quality | 163.64% | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 9.79 |
F-Score6
WACC8.68%
ROIC/WACC1.75
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y47.72%
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
EPS Next 5YN/A
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
Revenue Next Year18%
Revenue Next 2Y9.77%
Revenue Next 3Y10.75%
Revenue Next 5Y14.49%
EBIT growth 1Y-14.78%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year63.46%
EBIT Next 3Y22.08%
EBIT Next 5Y22.59%
FCF growth 1Y787.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y522.28%
OCF growth 3YN/A
OCF growth 5YN/A
MIMEDX GROUP INC / MDXG FAQ
Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
Can you provide the valuation status for MIMEDX GROUP INC?
ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.
What is the profitability of MDXG stock?
MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.
What is the financial health of MIMEDX GROUP INC (MDXG) stock?
The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.
What is the earnings growth outlook for MIMEDX GROUP INC?
The Earnings per Share (EPS) of MIMEDX GROUP INC (MDXG) is expected to grow by 47.72% in the next year.